Syngene International Limited Bombay S.E.

Equities

SYNGENE

INE398R01022

Biotechnology & Medical Research

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-05-03 am EDT			5-day change	1st Jan Change
678.7 ^INR	-1.27%		-2.80%	-3.20%

Apr. 28	Syngene International Limited Submits an Appeal to the National Faceless Appeal Centre, for Assessment Year 2022-23	CI
Apr. 26	Jefferies Downgrades Syngene International to Underperform From Hold, Adjusts Price Target to INR620 From INR690	MT

Syngene International Limited Provides Earnings Guidance for the Year 2021

July 22, 2020 at 05:00 am EDT

Syngene International Limited announced that based on the current visibility of the order book on a full year basis, The company expects low double-digit growth in revenues. The company expects PAT for the full year 2021 to be at similar level as in 2020.

Latest news about Syngene International Limited

Syngene International Limited Submits an Appeal to the National Faceless Appeal Centre, for Assessment Year 2022-23	Apr. 28	CI
Jefferies Downgrades Syngene International to Underperform From Hold, Adjusts Price Target to INR620 From INR690	Apr. 26	MT
Transcript : Syngene International Limited, Q4 2024 Earnings Call, Apr 25, 2024	Apr. 25
Syngene International Limited Submits an Appeal to the Commissioner of Income-Tax-12, Bangalore, for Assessment Year 2017-18 and 2018-19	Apr. 24	CI
Syngene International Limited Recommends Final Dividend for the Financial Year 2024	Apr. 24	CI
Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	Apr. 24	CI
Syngene International Limited Reports Earnings Results for the Full Year Ended March 31, 2024	Apr. 24	CI
Syngene International Limited Submits an Appeal to the Commissioner of Income-Tax-12, Bangalore, for Assessment Year 2013-14 and 2014-15	Apr. 22	CI
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes	Apr. 12	RE
Syngene Biologics Manufacturing Facility to Be Operational for U.S. and European Customers from Mid-Year	Mar. 14	CI
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	Feb. 27	RE
Jefferies Adjusts Syngene International’s Price Target to INR690 From INR770, Keeps at Hold	Jan. 26	MT
Syngene International Posts Gains in Fiscal Q3 Consolidated Net Profit	Jan. 26	MT
Transcript : Syngene International Limited, Q3 2024 Earnings Call, Jan 25, 2024	Jan. 25
Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 25	CI
Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024	Jan. 25	CI
Syngene International Completes Acquisition of Stelis Biopharma's Biologics Plant	Dec. 04	MT
Syngene International Limited completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion.	Nov. 30	CI
FOCUS -Indian drug manufacturers benefit from Big Pharma interest beyond China	Nov. 26	RE
Syngene International COO Steps Down	23-10-31	MT
Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024	23-10-31	CI
Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director	23-10-25	CI
Transcript : Syngene International Limited, Q2 2024 Earnings Call, Oct 18, 2023	23-10-18
Syngene International's Consolidated Profit Jumps in Fiscal Q2; Shares Slump 7%	23-10-18	MT
Syngene International Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-17	CI

Chart Syngene International Limited

Duration

Period

More charts

Company Profile

Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.

Sector

Biotechnology & Medical Research

Calendar

2024-07-23 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Syngene International Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

680.5 INR

Average target price

725.1 INR

Spread / Average Target

+6.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research